Trial Profile
Phase 2 Single Arm Trial of Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jan 2024
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Cisplatin (Primary) ; Paclitaxel (Primary) ; Carboplatin
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms CACTUX
- 02 Jan 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 02 Jan 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 01 Aug 2023 Planned End Date changed from 30 Jun 2023 to 31 Dec 2023.